Washington, D.C. (April 30, 2019) – Today, Representatives Elijah E. Cummings (D-MD), Chairman of the Committee on Oversight and Reform; Jerrold Nadler (D-NY), Chairman of the House Committee on the Judiciary; and Karen Bass (D-CA), Chairwoman of the Subcommittee on Crime, Terrorism and Homeland Security; reintroduced the Record Expungement Designed to Enhance Employment (REDEEM) Act on the last d... Read more »
Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 2374, the Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (Stop STALLING Act): “H.R. 2374, the ‘Stop STALLING Act,’ takes an important step toward lowering drug prices and increasing competition in health care markets. It does t... Read more »
Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 2376, the Prescription Pricing for the People Act of 2019: “H.R. 2376, the ‘Prescription Pricing for the People Act of 2019,’ would require the Federal Trade Commission to conduct a comprehensive report on the state of competition in the drug supply chain. “In particular... Read more »
Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 (CREATES Act): “H.R. 965, the ‘Creating and Restoring Equal Access to Equivalent Samples Act of 2019,’ or the ‘CREATES Act,’ is bipartisan legislation that would substantially lower drug price... Read more »
Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 2375, the Preserve Access to Affordable Generics and Biosimilars Act: “H.R. 2375, the ‘Preserve Access to Affordable Generics and Biosimilars Act’ is one of a series of bipartisan measures that we are considering today to address the critical need to lower the soaring co... Read more »
In a victory for Members of Congress, Judge Emmet Sullivan of the U.S. District Court for the District of Columbia has now denied, in full, President Trump’s motion to dismiss the challenge brought by roughly 200 Members of the Senate and House of Representatives, to hold him accountable to the Constitution’s Foreign Emoluments Clause. On learning this news, the lead plaintiffs and their counsel i... Read more »
Today, House Judiciary Committee Chairman Jerrold Nadler released a statement in response to reports that Special Counsel Robert Mueller wrote to Attorney General William Barr last month to object to the Attorney General’s summary of his report: “The Washington Post reports that Special Counsel Mueller wrote to Attorney General Barr last month to object to the Attorney General’s summary of his wor... Read more »
Washington, D.C. – Today, House Judiciary Chairman Jerrold Nadler (D-NY) delivered the following opening remarks during a Subcommittee on Constitution, Civil Rights and Civil Liberties hearing on the Equal Rights Amendment: "Thank you Chairman Cohen for convening this critical hearing. "The first version of the Equal Rights Amendment was proposed nearly one hundred years ago by Alice Paul, who he... Read more »
On April 30, 2019 at 2pm, the House Judiciary Committee will consider four bills to address prescription drug pricing, including H.R. 965, the CREATES Act; H.R. 2375, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 2374, the Stop STALLING Act; and H.R. 2376, the Prescription Pricing for the People Act of 2019. Date: April 30, 2019 Time: 2:00 p.m. Location: 2141 Rayburn House O... Read more »
Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) and Ranking Member Doug Collins (R-GA) introduced H.R. 2375, the bipartisan Preserve Access to Affordable Generics and Biosimilars Act. This legislation strengthens the Federal Trade Commission’s (FTC) ability to challenge settlement agreements between large brand drug companies and generic drug companies in court, which will help low... Read more »
